Patients with gastric or gastroesophageal junction cancers are enrolled in the expansion portion of the study. Credit: PopTika/Shutterstock.com.

Elevation Oncology has dosed the first patient in a Phase I clinical trial of the fully human monoclonal antibody EO-3021 to treat advanced solid tumours likely to express Claudin 18.2.

The multi-centre, open-label, dose escalation and expansion study will assess the tolerability, safety, and preliminary anti-tumour activity of EO-3021. It aims to enrol nearly 120 patients.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Patients with advanced unresectable or metastatic gastric, gastroesophageal junction, pancreatic or esophageal cancers are anticipated to be enrolled in the dose escalation portion of the study.

In the expansion part, patients with advanced unresectable or metastatic gastric or gastroesophageal junction cancers will be further assessed using EO-3021.

The study will also evaluate the association of Claudin 18.2 expression and objective response, as an additional objective measure.

Elevation Oncology chief medical officer Valerie Malyvanh Jansen said: “Claudin 18.2 has emerged as a promising therapeutic target in gastric cancer and other solid tumours.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Based on preclinical and early clinical data, EO-3021 represents a potentially safer and more effective therapeutic option for patients with advanced solid tumours that likely express Claudin 18.2, including gastric and gastroesophageal junction cancers.

“We look forward to evaluating the potential of EO-3021 and expect to report preliminary data on safety and anti-tumour activity from our Phase I study during the first half of 2025.”

Also known as SYSA1801, the antibody-drug conjugate EO-3021 is site-specifically conjugated to the cytotoxic agent monomethyl auristatin E through a cleavable linker, with a drug-to-antibody ratio of 2.

It delivers a cytotoxic payload to Claudin 18.2-expressing cancer cells directly for increasing anti-tumour activity and reducing payload-associated toxicities.